Union Bancaire Privee UBP SA Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Union Bancaire Privee UBP SA bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, Holdings Channel reports. The institutional investor bought 3,000 shares of the medical device company’s stock, valued at approximately $225,000.

Other large investors have also added to or reduced their stakes in the company. Versant Capital Management Inc bought a new position in DexCom in the fourth quarter valued at about $25,000. Riverview Trust Co increased its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in shares of DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the period. RPg Family Wealth Advisory LLC purchased a new position in shares of DexCom in the third quarter worth approximately $57,000. Finally, Park Place Capital Corp grew its position in DexCom by 3,516.7% during the fourth quarter. Park Place Capital Corp now owns 868 shares of the medical device company’s stock valued at $68,000 after buying an additional 844 shares during the period. Institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on DXCM. JPMorgan Chase & Co. boosted their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Oppenheimer lowered their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Citigroup increased their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Royal Bank of Canada lowered their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $99.29.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.30% of the stock is currently owned by company insiders.

DexCom Trading Down 2.2 %

Shares of DXCM opened at $86.43 on Thursday. The firm’s fifty day moving average is $80.00 and its two-hundred day moving average is $76.52. The stock has a market cap of $33.76 billion, a PE ratio of 51.75, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.